Oxaliplatin Induces Cell Cycle Arrest and Apoptosis in T-leukemia Cells through Mitochondrial and PI3K/Akt Signaling Pathways

doi:10.21127/yaoyimr20210003

Abstract

Abstract: Oxaliplatin (L-OHP) is a new platinum anticancer drug, which is used for the treatment of metastatic colorectal cancer or the adjuvant treatment of stage III colon cancer. T-cell acute lymphoblastic leukemias (T-ALLs) are invasive thymocytic malignant tumors with poor prognosis. The purpose of this study was to evaluate the cytotoxic effect of L-OHP on human T-ALL cell lines MOLT-4, Jurkat, CCRF-CEM, and CEM/C1 cells. The CCK-8 method results showed that L-OHP significantly inhibited T-ALL cells proliferation. The inhibition of these T-ALL cells prolife by L-OHP seems to be related to the induction of cell cycle arrest. The effect of L-OHP on the cell cycle distribution of T-ALL cells varies with cell types. As to cells apoptosis, Annexin V/Propidium iodide assay disclosed that L-OHP prominently induced T-ALL cells apoptosis by activating the pathways of mitochondrial biogenesis and is more sensitive to MOLT-4 cells. Western blot analysis showed that L-OHP treatment could promote apoptosis through down-regulated Bcl-2 protein level, up-regulated Bax and caspase-9 proteins levels and cell cycle arrest by inhibiting the PI3K/Akt signaling pathway in MOLT-4 cells. Our results indicate that L-OHP, as a new type of platinum anticancer drug, may attract more attention in the future treatment of T-ALL.

Key words: oxaliplatin, lymphoblastic leukemia, mitochondrial pathway, apoptosis, cell cycle

Mengcheng Li, Yongpeng Wang, Lei Tian, Afsar Khan, Yudan Wang, Yaping Liu, Meilian Yang, Jianxin Cao, Guiguang Cheng, and Tianrui Zhao. Oxaliplatin Induces Cell Cycle Arrest and Apoptosis in T-leukemia Cells through Mitochondrial and PI3K/Akt Signaling Pathways[J]. Medicine Research, 2021, 5(2): 210003-210003.

References

[1] Xu, Y.; Li, X.; Su, X. Itraq-based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells. Oncol. Rep. 2019, 43, 201–217.
[2] Kang, L.; Tian, Y.; Xu, S.; Chen, H. Oxaliplatin-induced peripheral neuropathy: Clinical features, mechanisms, prevention and treatment. J. Neurol. 2020, DOI: 10.1007/s00415-020-09942-w.
[3] Canta, A.; Chiorazzi, A.; Pozzi, E.; Fumagalli, G.; Monza, L.; Meregalli, C.; Carozzi, V. A.; Rodriguez-Menendez, V.; Oggioni, N.; Nasstrom, J.; Marmiroli, P.; Cavaletti, G. Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity. Antioxidants 2020, 9, 594.
[4] Bonaccorso, P.; Bugarin, C.; Buracchi, C.; Fazio, G.; Gaipa, G. Single-cell profiling of pediatric t-cell acute lymphoblastic leukemia: Impact of pten exon 7 mutation on pi3k/akt and jak–stat signaling pathways. Cytom. Part. B-clin. Cy. 2020, 491–503.
[5] Li, G.; Gao, L.; Zhao, J.; Liu, D.; Hu, M. Lncrna anril/mir-7-5p/tcf4 axis contributes to the progression of t cell acute lymphoblastic leukemia. Cancer Cell Int. 2020, 20, 335.
[6] Wu, K. N.; Zhao, Y. M.; He, Y.; Wang, B. S.; Du, K. L.; Fu, S.; Hu, K. M.; Zhang, L. F.; Liu, L. Z.; Hu, Y. X. Rapamycin interacts synergistically with idarubicin to induce t-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via akt/mammalian target of rapamycin and extracellular signal-related kinase signalin. Leukemia Lymphoma 2014, 55, 668–676.
[7] Mcneer, J. L.; Bleyer, A. Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. Pediatr. Blood Cancer 2018, e26989.
[8] Jaime-Pérez, J. C.; Fernández, L. T.; Jiménez-Castillo, R. A.; Gómez-De León, A.; Cantú-Rodríguez, O. G.; Gutiérrez-Aguirre, C. H.; Gómez-Almaguer, D. Age acts as an adverse independent variable for survival in acute lymphoblastic leukemia: Data from a cohort in northeast mexico. Cl. Lymph. Myelom. Leuk. 2017, 590–594.
[9] Garcia, E. G.; Veloso, A.; Oliveira, M. L.; Allen, J. R.; Langenau, D. M. Prl3 enhances t-cell acute lymphoblastic leukemia growth through suppressing t-cell signaling pathways and apoptosis. Leukemia 2020, 1–12.
[10] Ko, R. H.; Ji, L.; Barnette, P.; Bostrom, B.; Hutchinson, R.; Raetz, E.; Seibel, N. L.; Twist, C. J.; Eckroth, E.; Sposto, R. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia consortium study. J. Clin. Oncol. 2010, 28, 648–654.
[11] Schrappe, M.; Hunger, S. P.; Pui, C. H.; Saha, V.; Gaynon, P. S.; Baruchel, A.; Conter, V.; Otten, J.; Ohara, A.; Versluys, A. B. Outcomes after induction failure in childhood acute lymphoblastic leukemia. New Engl. J. Med. 2012, 366, 1371–1381.
[12] Kong, Y.; Zhao, S.; Tian, H.; Hai, Y. Gas2 promotes cell proliferation and invasion and suppresses apoptosis in pediatric t-cell acute lymphoblastic leukemia and activates wnt/β-catenin pathway. OncoTargets Ther. 2020, 13, 1099–1108.
[13] Malumbres, M.; Barbacid, M. Cell cycle, cdks and cancer: A changing paradigm. Nat. Rev. Cancer 2009, 9, 153–166.
[14] Roskoski, R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol. Res. 2019, 139, 471–488.
[15] Wang, L.; Yao, L.; Li, X.; Chen, J.; Lou, C.; Wang, Y. Stephanthraniline a suppresses proliferation of hct116 human colon cancer cells through induction of caspase-dependent apoptosis, dysregulation of mitochondrial function, cell cycle arrest and regulation of akt/p38 signaling pathways. J. Toxicol. Sci. 2019, 44, 523–533.
[16] Fan, M.; Chen, X.; Luo, X.; Zhang, H.; Liu, Y.; Zhang, Y.; Wu, J.; Zhao, C.; Zhao, P. Diversity of endophytic fungi from the leaves of vaccinium dunalianum. Lett. Appl. Microbiol. 2020, 71, 479–489.
[17] Ni, K.; Lan, G.; Veroneau, S. S.; Duan, X.; Song, Y.; Lin, W. Nanoscale metal-organic frameworks for mitochondria-targeted radiotherapy-radiodynamic therapy. Nat. Commun. 2018, 9, 4321.
[18] Mori, K.; Uchida, T.; Yoshie, T.; Mizote, Y.; Ishikawa, F.; Katsuyama, M.; Shibanuma, M. A mitochondrial ros pathway controls matrix metalloproteinase 9 levels and invasive properties in ras-activated cancer cells. FEBS J. 2019, 286, 459–478.
[19] Zhang, X.; Xu, L.; Yang, T. Mir-31 modulates liver cancer hepg2 cell apoptosis and invasion via rock1/f-actin pathways. Onco Targets Ther. 2020, 13, 877–888.
[20] Jin, Q.; Li, R.; Hu, N.; Xin, T.; Zhu, P.; Hu, S.; Ma, S.; Zhu, H.; Ren, J.; Zhou, H. Dusp1 alleviates cardiac ischemia/reperfusion injury by suppressing the mff-required mitochondrial fission and bnip3-related mitophagy via the jnk pathways. Redox Biol. 2018, 14, 576.
[21] Li, Q.; Qiu, W.; Zhu, Q.; Zu, Y.; Deng, X.; Zhao, T.; Jiang, C.; Zhang, L. Camptothecin-20(s)-o-[n-(3’α,12’α-dihydroxy-24’-carbonyl-5’β- cholan)]-lysine, a novel camptothecin analogue, induces apoptosis towards hepatocellular carcinoma smmc-7721 cells. Molecules 2011, 16, 7803–7814.
[22] Orrenius, S. Mitochondrial regulation of apoptotic cell death. Toxicol. Lett. 2004, 149, 19–23.
[23] Verkhratsky, A.; Toescu, E. C. Endoplasmic reticulum Ca2+ homeostasis and neuronal death. J. Cell Mol. Med. 2003, 7, 351–361.
[24] Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Calcium: Regulation of cell death: The calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4, 552–565.
[25] Yoneyama, K. Validation of confocal laser scanning microscopy for detecting intracellular calcium heterogeneity in liver slices. J. Pharmacol. Tox. Met. 2001, 45, 187–193.
[26] Fu, Y.; Yi, Z.; Yan, Y.; Qiu, Z. Hydroxycamptothecin-induced apoptosis in hepatoma smmc-7721 cells and the role of mitochondrial pathway. Mitochondrion 2006, 6, 211–217.
[27] Han, J.; Goldstein, L. A.; Gastman, B. R.; Rabinowich, H. Interrelated roles for mcl-1 and bim in regulation of trail-mediated mitochondrial apoptosis. J. Biol. Chem. 2006, 281, 10153–10163.
[28] Haga, N.; Fujita, N.; Tsuruo, T. Mitochondrial aggregation precedes cytochrome c release from mitochondria during apoptosis. Oncogene 2003, 22, 5579–5585.
[29] Raisova, M.; Hossini, A. M.; Eberle, J.; Riebeling, C.; Wieder, T.; Sturm, I.; Daniel, P. T.; Orfanos, C. E.; Geilen, C. C. The bax/bcl-2 ratio determines the susceptibility of human melanoma cells to cd95/fas-mediated apoptosis. J. Invest. Dermatol. 2001, 117, 333–340.
[30] Schwarz, M.; Andrade-Navarro, M. A.; Gross, A. Mitochondrial carriers and pores: Key regulators of the mitochondrial apoptotic program. Apoptosis 2007, 12, 869–876.
[31] Laplante, M.; Sabatini, D. M. Mtor signaling in growth control and disease. Cell 2012, 149, 274–293.
[32] Evangelisti, C.; Chiarini, F.; Cappellini, A.; Paganelli, F.; Fini, M.; Santi, S.; Martelli, A. M.; Neri, L. M.; Evangelisti, C. Targeting wnt/β-catenin and pi3k/akt/mtor pathways in t-cell acute lymphoblastic leukemia. J. Cell Physiol. 2020, 235, 5413–5428.
[33] Zhang, L. N.; Zhao, L.; Yan, X. L.; Huang, Y. H. Loss of g3bp1 suppresses proliferation, migration, and invasion of esophageal cancer cells via wnt/β-catenin and pi3k/akt signaling pathways. J. Cell Physiol. 2019, 234, 20469–20484.
[34] Jefferies, M. T.; Cox, A. C.; Shorning, B. Y.; Meniel, V.; Griffiths, D.; Kynaston, H. G.; Smalley, M. J.; Clarke, A. R. Pten loss and activation of k-ras and β-catenin cooperate to accelerate prostate tumourigenesis. J. Pathol. 2017, 243, 442–456.
[35] Bressanin, D.; Evangelisti, C.; Ricci, F.; Tabellini, G.; Martelli, A. M. Harnessing the pi3k/akt/mtor pathway in t-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. Oncotarget 2012, 3, 811–823.
[36] Evangelisti, C.; Cappellini, A.; Oliveira, M.; Fragoso, R.; Barata, J. O. T.; Bertaina, A.; Locatelli, F.; Simioni, C.; Neri, L. M.; Chiarini, F. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in b-cell acute lymphoblastic leukemia. J. Cell Physiol. 2018, 233, 1796–1811.
[37] Lonetti, A.; Antunes, I.; Chiarini, F.; Orsini, E.; Buontempo, F.; Ricci, F.; Tazzari, P. L.; Pagliaro, P.; Melchionda, F.; Pession, A. Activity of the pan-class i phosphoinositide 3-kinase inhibitor nvp-bkm120 in t-cell acute lymphoblastic leukemia. Leukemia 2014, 28, 1196–1206.